Delivery Order SPE2DB22D2006-SPE2DB25FV5VY

Award Date 10/24/24
Potential Completion Date 11/15/24
Potential Value $6.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of ANDEXXA 200 MG VIALS. The contract has a ceiling value of $26,016.45 and an ultimate completion date of July 17, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,931.53, is a delivery order for 4,568,075,871 vials of the medication ANDEXXA 200 MG. The contract is a firm fixed-price agreement with a period of performance ending on May 20, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,672.15, is for the supply of ANDEXXA 200 MG VIALS, a pharmaceutical product. The contract is a firm fixed-price delivery order with a completion date of May 23, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for ANDEXXA 200 MG VIALS. The $20,794.59 firm fixed price contract has a completion date of July 21, 2025. Amerisourcebergen Drug Corp is the prime contractor, and there is no set-aside designation for this award. This delivery order is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award to Amerisourcebergen Drug Corp, awarded by the Medical Supply Chain division of the Department of Defense (DoD), provides for the delivery of ANDEXXA 200 MG VIALS, a critical pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price valued at $6,658.72, with an ultimate completion date of June 13, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) with the Defense...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA), a defense agency. The $8,672.15 firm fixed-price delivery order is for ANDEXXA 200 MG VIALS and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,928.53 firm-fixed-price contract has an ultimate completion date of November 18, 2024 and is not designated with a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a firm fixed price of $1,472.40 and an ultimate completion date of December 31, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,028.56 firm-fixed-price contract will run through February 2025 and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,977.12 firm fixed-price contract has a period of performance through March 2025 and is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
  • SPE2DB22D2006
    Indefinite Delivery Contract
  • SPE2DB22D2006-SPE2DB25FV5VY
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The $6,658.73 firm-fixed-price contract provides for the delivery of ANDEXXA 200 MG vials, a specialized medication. The contract has a completion date of November 15, 2024.

AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as the primary vehicle for the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also has a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024 for similar medical commodities. These IDCs enable efficient government procurement of essential pharmaceutical and medical items for military personnel, veterans, and other federal beneficiaries.

Generated 1/23/25, 9:27 AM